撤稿：FTO联合CEA或CYFRA21-1在非小细胞肺癌中的诊断价值
Retracted: Diagnostic Value of FTO Combined with CEA or CYFRA21-1 in Nonsmall Cell Lung Cancer.
作者信息
And Alternative Medicine Evidence-Based Complementary
出版信息
Evid Based Complement Alternat Med. 2023 Jun 21;2023:9843134. doi: 10.1155/2023/9843134. eCollection 2023.
Abstract
[This retracts the article DOI: 10.1155/2021/1436088.].
摘要
[本文撤回文章DOI: 10.1155/2021/1436088。]
相似文献
1
Retracted: Diagnostic Value of FTO Combined with CEA or CYFRA21-1 in Nonsmall Cell Lung Cancer.撤稿：FTO联合CEA或CYFRA21-1在非小细胞肺癌中的诊断价值
Evid Based Complement Alternat Med. 2023 Jun 21;2023:9843134. doi: 10.1155/2023/9843134. eCollection 2023.
2
Diagnostic Value of FTO Combined with CEA or CYFRA21-1 in Nonsmall Cell Lung Cancer.FTO联合CEA或CYFRA21-1在非小细胞肺癌中的诊断价值
Evid Based Complement Alternat Med. 2021 Oct 14;2021:1436088. doi: 10.1155/2021/1436088. eCollection 2021.
3
Thymidine kinase 1 combined with CEA, CYFRA21-1 and NSE improved its diagnostic value for lung cancer.胸苷激酶1联合癌胚抗原、细胞角蛋白19片段和神经元特异性烯醇化酶可提高其对肺癌的诊断价值。
Life Sci. 2018 Feb 1;194:1-6. doi: 10.1016/j.lfs.2017.12.020. Epub 2017 Dec 14.
4
Diagnostic utility of serum and pleural fluid carcinoembryonic antigen, and cytokeratin 19 fragments in patients with effusion from nonsmall cell lung cancer.血清和胸水癌胚抗原及细胞角蛋白19片段在非小细胞肺癌伴胸腔积液患者中的诊断价值
J Carcinog. 2015 Nov 27;14:7. doi: 10.4103/1477-3163.170662. eCollection 2015.
5
Application Value of Serum TK1 and PCDGF, CYFRA21-1, NSE, and CEA plus Enhanced CT Scan in the Diagnosis of Nonsmall Cell Lung Cancer and Chemotherapy Monitoring.血清胸苷激酶1、血小板衍生生长因子、细胞角蛋白19片段、神经元特异性烯醇化酶及癌胚抗原联合增强CT扫描在非小细胞肺癌诊断及化疗监测中的应用价值
J Oncol. 2022 Mar 25;2022:8800787. doi: 10.1155/2022/8800787. eCollection 2022.
6
Diagnostic Value and Clinical Significance of Combined Detection of Serum Markers CYFRA21-1, SCC Ag, NSE, CEA and ProGRP in Non-Small Cell Lung Carcinoma.血清标志物CYFRA21-1、SCC Ag、NSE、CEA和ProGRP联合检测在非小细胞肺癌中的诊断价值及临床意义
Clin Lab. 2020 Nov 1;66(11). doi: 10.7754/Clin.Lab.2020.191243.
7
Retracted: The Role of Change Rates of CYFRA21-1 and CEA in Predicting Chemotherapy Efficacy for Non-Small-Cell Lung Cancer.撤稿：细胞角蛋白19片段21-1（CYFRA21-1）和癌胚抗原（CEA）变化率在预测非小细胞肺癌化疗疗效中的作用。
Comput Math Methods Med. 2023 Oct 18;2023:9786104. doi: 10.1155/2023/9786104. eCollection 2023.
8
Retracted: Impact of HSP90, CEA, NSE, SCC, and CYFRA21-1 on Lung Cancer Patients.撤回：热休克蛋白90、癌胚抗原、神经元特异性烯醇化酶、鳞状细胞癌抗原和细胞角蛋白19片段对肺癌患者的影响。
J Healthc Eng. 2023 Oct 11;2023:9796148. doi: 10.1155/2023/9796148. eCollection 2023.
9
[Clinical value of tumor-associated autoantibodies in diagnosis of early non-small cell lung cancer].肿瘤相关自身抗体在早期非小细胞肺癌诊断中的临床价值
Zhonghua Yu Fang Yi Xue Za Zhi. 2021 Dec 6;55(12):1426-1434. doi: 10.3760/cma.j.cn112150-20210511-00461.
10
The value of combined detection of CEA, CYFRA21-1, SCC-Ag, and pro-GRP in the differential diagnosis of lung cancer.癌胚抗原（CEA）、细胞角蛋白19片段（CYFRA21-1）、鳞状细胞癌抗原（SCC-Ag）和胃泌素释放肽前体（pro-GRP）联合检测在肺癌鉴别诊断中的价值
Transl Cancer Res. 2021 Apr;10(4):1900-1906. doi: 10.21037/tcr-21-527.
引用本文的文献
1
FTO in Lung Cancer: Its Progression and Therapeutic Potential.FTO 在肺癌中的作用：进展与治疗潜力。
Comb Chem High Throughput Screen. 2024;27(15):2301-2307. doi: 10.2174/0113862073281598240227072839.
本文引用的文献
1
Diagnostic Value of FTO Combined with CEA or CYFRA21-1 in Nonsmall Cell Lung Cancer.FTO联合CEA或CYFRA21-1在非小细胞肺癌中的诊断价值
Evid Based Complement Alternat Med. 2021 Oct 14;2021:1436088. doi: 10.1155/2021/1436088. eCollection 2021.
Zotero 插件